Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014
Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00003375 (A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma), which is not on this map. Cited by 58 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma
Who cites it
58 citing papers in PubMed, 6 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Cognitive outcomes after multimodal treatment in adult glioma patients: A meta-analysis.Neuro-oncology · 2023Pooled it
- Influences on cognitive outcomes in adult patients with gliomas: A systematic review.Frontiers in oncology · 2022Pooled it
- A systematic review of extracellular vesicles as non-invasive biomarkers in glioma diagnosis, prognosis, and treatment response monitoring.Molecular biology reports · 2021Pooled it
- Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas.The Cochrane database of systematic reviews · 2020Pooled it
- Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma.The Cochrane database of systematic reviews · 2019Pooled it
- Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas.The Cochrane database of systematic reviews · 2015Pooled it
- Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.Neuro-oncology · 2021Trial
- [Not Available].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2016Trial
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.The New England journal of medicine · 2016Trial
- Trial
- Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Current Treatment Options for Adult Grade 2 IDH-mutant Diffuse Gliomas in the Vorasidenib Era: Patient Selection, Sequencing, and Practical Management.Current treatment options in oncology · 2026Review
- Article
- Cognitive Impairment in Patients with Glioma: Mechanisms, Assessment, and Emerging Therapeutic Strategies.Cancers · 2026Review
- Isocitrate Dehydrogenase-Mutant Astrocytomas: Risk Stratification and Therapeutic Advance.MedComm · 2026Review
- Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study.Neuro-oncology · 2026Article
- Factors associated with cognitive impairment in long-term IDH-mutant glioma survivors.Journal of neuro-oncology · 2025Article
- Low tumour burden is associated with observation after surgery in patients with grade 2 astrocytoma and oligodendroglioma: results from the prospective multicentre LoG-Glio registry.Journal of neuro-oncology · 2025Article
- Neurocognitive function in lower grade glioma patients selected for proton radiotherapy: real-world data from a prospective cohort study.Journal of neuro-oncology · 2025Article
- The effect of radiation dose to the brain on early self-reported cognitive function in brain and head-and-neck cancer patients.Clinical and translational radiation oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
purposeThe addition of PCV (procarbazine, lomustine, and vincristine) chemotherapy to radiotherapy (RT) for patients with WHO grade 2 glioma improves progression-free survival (PFS). The effect of therapy intensification on cognitive function (CF) remains a concern in this population with substantial long-term survival. PATIENTS AND
methodsA total of 251 patients with WHO grade 2 glioma age ≥ 40 years with any extent of resection or age < 40 years with subtotal resection/biopsy were randomly assigned to RT (54 Gy) or RT plus PCV. We observed 111 patients age < 40 years with gross total resection. CF was assessed by Mini-Mental State Examination (MMSE) at baseline and years 1, 2, 3, and 5.
resultsOverall, few patients experienced significant decline in MMSE score. There were no significant differences in the proportion of patients experiencing MMSE score decline between the randomized study arms at any time point. Both study arms experienced a significant gain in average MMSE score longitudinally over time, with no difference between arms.
conclusionThe MMSE is a relatively insensitive tool, and subtle changes in CF may have been missed. However, the addition of PCV to RT did not result in significantly higher rates of MMSE score decline than RT alone through 5 years of follow-up. Patients in both randomly assigned arms experienced a statistically significant average MMSE score increase over time, with no difference between arms. The addition of PCV chemotherapy to RT improves PFS without excessive CF detriment over RT alone for patients with low-grade glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.